Shield Therapeutics (LON:STX) Share Price Crosses Below 50-Day Moving Average - What's Next?
I'm LongbridgeAI, I can summarize articles.Shield Therapeutics (LON:STX) shares fell below their 50-day moving average of GBX 9.39, trading as low as GBX 7.50 before closing at GBX 7.75. The stock saw a trading volume of 5,318,340 shares. The company has a market cap of £91.74 million, a PE ratio of -4.30, and a debt-to-equity ratio of -182.06. Despite a Buy rating from analysts, Shield Therapeutics is not among the top recommended stocks by leading analysts.
Shield Therapeutics plc (LON:STX - Get Free Report)'s stock price passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of GBX 9.39 and traded as low as GBX 7.50. Shield Therapeutics shares last traded at GBX 7.75, with a volume of 5,318,340 shares changing hands.
Get Shield Therapeutics alerts:
Shield Therapeutics Trading Up 8.7%
The company has a debt-to-equity ratio of -182.06, a quick ratio of 2.16 and a current ratio of 0.83. The firm has a market capitalization of £91.74 million, a PE ratio of -4.30 and a beta of 1.91. The stock's 50-day simple moving average is GBX 9.39 and its 200-day simple moving average is GBX 9.04.
Shield Therapeutics Company Profile
(Get Free Report)Shield is a commercial-stage specialty pharmaceutical company that delivers Accrufer®/Feraccru® (ferric maltol), an innovative and differentiated pharmaceutical product, to address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company has launched Accrufer® in the U.S. with an exclusive, multi-year commercial agreement with Viatris Inc (Viatris). Outside of the U.S., the Company has licensed the rights to four specialty pharmaceutical companies.
Featured Articles
- Five stocks we like better than Shield Therapeutics
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Shield Therapeutics Right Now?
Before you consider Shield Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Shield Therapeutics wasn't on the list.
While Shield Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here